



Press Release

## **Cipla launches Q-TIB globally, a novel fixed dose combination in a single tablet for T.B. prophylaxis in HIV**

**Mumbai, India, November 30, 2017:** Cipla Ltd, a global pharmaceutical company, today announced that it has received an approval for its product Q-TIB from World Health Organisation (WHO). Q-TIB is a novel fixed dose combination in a single tablet. This is the first time that such a combination has been made available in the world. Cipla will market the product globally.

Q-TIB will help prevent tuberculosis infection in people living with HIV. People living with HIV face a challenged immune system and are prone to opportunistic infections, which constitute the major source of premature deaths among them. As per Global TB Report, 2016, by WHO, about one million people died of AIDS-related illness. Most of them succumbed to opportunistic infections, and among them, 400,000 died of tuberculosis.

### **About Cipla Ltd.**

About Cipla Ltd. Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. In the last 80+ years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 80 countries. Our portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001. Cipla's research and development focuses on developing innovative products and drug delivery systems.

[www.cipla.com](http://www.cipla.com)

### **Media Contacts:**

#### **Corporate Communications**

Pallavi Golar

E Mail: [pallavi.golar@cipla.com](mailto:pallavi.golar@cipla.com)

#### **Investor Relations**

Naveen Bansal

E-Mail: [Naveen.Bansal1@Cipla.com](mailto:Naveen.Bansal1@Cipla.com)